The 3D bioprinting space is certainly beginning to get the attention of investors. There are now several companies with the funding needed to develop techniques which could one day lead to a major breakthrough in regenerative medicine.
Today, Isis Innovation, the University of Oxford’s research commercialisation company, announced that OxSyBio Ltd., a spin-out from the University, has raised £1 million from IP Group plc to develop their proprietary 3D droplet printing technology. Professor Hagan Bayley’s group at the University’s Department of Chemistry are the ones who came up with this approach to 3d bioprinting. They used thousands of tiny droplets, coated with a film that mimics the external membrane of an actual living cell. The team then studded the membranes with protein pores, making them act just like simplified cells.
The droplets, which OxSyBio prints, can transmit electrical pulses, like the ones that are used by living cells, to communicate in the human nervous system.
“We also aim to integrate printed tissue-like materials with living tissues, and to print materials that themselves contain living cells. Our long-term goal is to develop a synthetic-tissue printer that a surgeon can use in the operating theatre. In ten years’ time, the use of pieces of synthetic tissue will be commonplace. The fabrication of complex synthetic organs is a more distant prospect. I am delighted to be working with Isis and IP Group to accelerate the development of our new company, OxSyBio. Our goal is to establish ourselves at the frontline of regenerative medicine,” stated Professor Hagan Bayley.
Regenerative medicine is certainly a field that will garner a lot of investor interest over the coming years, as the prospects of 3D printing organs, patches, and other living tissue increases because of natural technological progress.
Alan Aubrey, Chief Executive Officer of IP Group, said: “Synthetic biology and regenerative medicine will be central to the development of healthcare in the 21st century and IP Group is pleased to support OxSyBio as it seeks to develop products that will help to realize the potential of these exciting and growing areas.”
OxSyBio was formed just last month and is based in London England. You can participate in the discussion about OxSyBio, and their 3D droplet bioprinting technology at 3DPrintBoard.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
3D Printing Financials: Prodways’ Q1 2024 Revenue Drop and Accounting Overhaul
Prodways (EPA: PWG) has released its earnings report for the first quarter of 2024, announcing modest revenue. This result is lower than last year’s, reflecting the company’s ongoing adjustments to...
3D Printing Financials: Prodways Faces Headwinds, Cuts Jewelry Printers and Cristal Dental Lab for Turnaround
Prodways (EPA: PWG), a European leader in industrial 3D printing, encountered financial challenges in 2023, as revealed in its earnings report. The company saw a decline in revenue and profitability...
Printing Money Episode 12: Q3 2023 Earnings Reports with Troy Jensen, Cantor Fitzgerald
Episode 12 of Printing Money brings with it a slightly different approach, as Alex Kingsbury sits this one out while Danny runs the show. Equity research analyst Troy Jensen, now of Cantor...
3D Printing News Briefs, November 18, 2023: Depowdering, Jewelry Patterns, & More
We’re kicking off 3D Printing News Briefs with a little business today, as Horizon Microtechnologies invested in a micro AM platform from Boston Micro Fabrication, and Rivelin Robotics announced a...